NEWS / Stock

Novo Nordisk Shares Drop 15% After Weight Loss Drug Trial Results

Published Feb 23, 2026

Share:

A computer displays a declining stock chart with a percent symbol; in the foreground, a cracked cup, pill bottle—hinting at weight loss drug trial results—a scale, and red dumbbell sit on the desk.

Summary:

Novo Nordisk's stock fell 15% on February 23, 2026, after its weight loss drug CagriSema failed to show non-inferiority to Eli Lilly's drug.

Patients using CagriSema lost 23% of their weight after 84 weeks, compared to a 25.5% loss with Eli Lilly's tirzepatide.

Novo Nordisk's shares reached 256 Danish kroner, the lowest since June 2021.

Trial Results and Stock Impact

Novo Nordisk saw a significant drop in its stock price, falling 15% on February 23, 2026. This decline followed the announcement that its weight loss drug, CagriSema, did not meet its key goal of demonstrating non-inferiority in weight loss when compared to Eli Lilly's tirzepatide in clinical trials.

The trial results showed that patients taking CagriSema achieved a weight loss of 23% after 84 weeks, while those taking a 15 mg dose of tirzepatide lost 25.5% during the same period.

Current Stock Performance

Novo Nordisk's shares were last seen trading at 256 Danish kroner, marking the lowest level for the company since June 2021. In contrast, Eli Lilly's stock experienced a rise of 3.5% in premarket trading after the trial results were released.

The stark difference in stock performance reflects the competitive landscape between the two companies in the weight loss medication market.

Market Challenges for Novo Nordisk

Novo Nordisk is currently facing several challenges that could impact its future performance. The company is dealing with increased competition not only from Eli Lilly but also from other competitors in the weight loss drug market.

Additionally, Novo Nordisk has been impacted by lower prices in the U.S. market and is experiencing a loss of exclusivity for its popular drugs, Wegovy and Ozempic, in certain regions.

Future Outlook and Predictions

Earlier this month, Novo Nordisk projected a decline in sales and profit growth of between 5% and 13% for 2026.

This forecast is influenced by the ongoing competition and pricing pressures in the market. CEO Mike Doustdar mentioned that stakeholders should expect the stock to decline further before it has a chance to recover.

Next Steps for CagriSema

Despite the setback, Novo Nordisk is not giving up on CagriSema. The company is exploring additional trials to test the drug, including higher-dose combinations.

The Chief Scientific Officer, Martin Holst Lange, expressed optimism about CagriSema, stating that it has the potential to be the first GLP-1/amylin-combination product available for people living with obesity. The company aims to demonstrate that cagrilintide adds significant benefits to semaglutide, leading to greater weight loss results.

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Recent News

May 25, 2026

The CLARITY Act Could Spark A Crypto "Yield-As-A-Service" Boom

May 25, 2026

The SEC Just Hit Pause On Letting Crypto Firms Trade U.S. Stocks On The Blockchain

May 25, 2026

Home Buyers And Sellers Are Finally Meeting In The Middle On Price

1 2 3 … 616 Next »

Blogs

How to Create Multiple Income Streams: A Beginner's Playbook

By Milena Thomas

Most people rely on a single income stream from their job - which is also the most heavily taxed.
Multiple income streams come from a mix of cash flow, dividends, side businesses, real estate, and royalties.
The fastest path for most beginners is starting with one extra stream - usually dividends or a side hustle - and stacking from there.

The 60/40 Portfolio Explained: A Beginner's Guide

By Nate Gregory

A 60/40 portfolio holds 60% in stocks and 40% in bonds (or other fixed income).
It's designed to balance growth from stocks with stability from bonds.
Your "right" mix depends on age, time horizon, income needs, and how well you sleep when markets drop.

How to Invest in Silver: A Beginner's Guide

By Jackson Moreland

Silver is both a precious metal and an industrial metal, used in solar panels, electronics, and medical tech.
Investors can buy silver four main ways: physical bars and coins, ETFs, mining stocks, or futures contracts.
Most beginners are best served by allocating a small slice of their portfolio to silver - usually between 1% and 3%.

Asset Allocation by Age: The Right Portfolio Mix at Every Stage of Life

By Andre Savage

Younger investors should hold mostly stocks because they have decades to recover from crashes and benefit from compounding.
Allocations gradually shift toward bonds and stable income as retirement approaches, but stocks remain important even past age 65 to outpace inflation.
Annual rebalancing is essential - it forces you to buy low and sell high while keeping your portfolio aligned with your actual life stage.

Stablecoin Explained: Why Some Cryptocurrencies Actually Aren't Volatile

By Jackson Moreland

Stablecoins are cryptocurrencies pegged to stable assets like the US dollar, giving crypto-style speed and access without the volatility of Bitcoin or Ethereum.
Fiat-backed stablecoins like USDC are the safest option, while algorithmic stablecoins have failed spectacularly and should generally be avoided.
Stablecoins fit a portfolio as cash reserves with better yields, a hedge against crypto volatility, and a fast, cheap rail for international transactions.

Buy Now, Pay Later Risks: Why This "Easy" Payment Method Is Dangerous to Your Wealth

By Nate Gregory

Buy now, pay later services like Klarna, Affirm, and Sezzle are debt products designed to feel harmless while keeping users in a cycle of overspending.
BNPL exploits psychological debt blindness, triggers late fees, and damages credit scores without helping users build positive credit history.
Building real wealth means waiting 30 days, paying upfront when you have the cash, and avoiding systems built to extract money from your future income.

Dividend Payout Ratio: The Secret Metric That Shows If a Stock Is Safe or Risky

By Jackson Moreland

Dividend payout ratio is total dividends paid divided by net income, showing the percentage of earnings a company returns to shareholders.
A 20-50% payout ratio is generally safe and sustainable, while ratios above 75% often signal a dividend cut is coming.
High dividend yields can be warning signs, not opportunities - safety and dividend growth matter more than the headline yield number.

Ethereum for Beginners: What It Is and Why Smart Investors Are Paying Attention

By Milena Thomas

Ethereum is a blockchain platform that runs smart contracts, while Ether (ETH) is the cryptocurrency that powers the network.
Use cases include decentralized finance, NFTs, gaming, supply chain tracking, and digital identity - many still experimental.
Most investors should treat Ethereum as a small allocation hedge using dollar-cost averaging, not a get-rich-quick lottery ticket.

Dollar Cost Averaging Strategy: How to Beat Emotion and Build Wealth Steadily

By Nate Gregory

Dollar cost averaging means investing the same amount at regular intervals regardless of what the market is doing.
The strategy automatically buys more shares when prices are low and fewer when prices are high, lowering your average cost over time.
DCA removes emotion, eliminates the need to time the market, and turns volatility into a mathematical advantage for long-term investors.

The BRRRR Strategy: How to Build Real Estate Wealth Without Big Money Down

By Andre Savage

BRRRR stands for Buy, Rehab, Rent, Refinance, Repeat - a five-step framework for scaling real estate without saving for big down payments.
The strategy works by buying distressed properties below market value, adding value through smart renovations, and pulling out equity through refinancing.
Tax advantages like depreciation and mortgage interest deductions make BRRRR a powerful tool for owners willing to manage tenants and contractors.

1 2 3 … 20 Next »